Cellectis and The Ohio State University, Through the Ohio State Innovation Foundation, Enter Into Licensing Agreement for Chimeric Antigen Receptor Technology Targeting Multiple Myeloma

Paris, January 13, 2015 - Cellectis SA (Alternext: ALCLS.PA) announces that it has entered into an exclusive license agreement with The Ohio State University, through the Ohio State Innovation Foundation, to develop and commercialize chimeric antigen receptor (CAR) technology targeting multiple myeloma cells.

The CAR technology licensed to Cellectis is related to CS1, an antigen that is over-expressed in multiple myeloma cells. Cellectis intends to pursue the development of a CS1 CAR T-cell program for this targeted indication.

Multiple myeloma is the second most common type of blood cancer with a five-year survival rate of 45%. This cancer represents a major unmet medical need.

André Choulika, Chief Executive Officer and Chairman of Cellectis stated "This agreement aligns with our CAR T-cell development strategy to bring innovative therapies to patients with cancer. We are pleased to have entered into this license agreement with Ohio State University since it is a major research center with unique and outstanding expertise in multiple myeloma."

Cellectis is currently developing three proprietary allogeneic CAR T-cell product candidates in the field of liquid tumors, targeting CD123 in acute myeloid leukemia, as well as CD38 and CS1 for multiple myeloma. Cellectis aims to file in 2015 an application for a Clinical Trial Authorization for its allogeneic UCART19 product candidate, which targets CD19 in acute lymphoblastic leukemia and chronic lymphocytic leukemia.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.